Earnings season brings clarity—and volatility. This week, retail giant Target (TGT) and AI-driven precision medicine company SOPHiA GENETICS (SOPH) reported earnings, providing insights into consumer spending and healthcare technology trends. The SPY edged up only +0.06% reflecting the mixed results.
Target's (TGT) stock rose after the company reported an earnings beat. Fourth quarter net sales of $30.5 billion were in line with company expectations, with Food & Beverage, Beauty, and Toys delivering net sales growth. The company also experienced stronger trends in Essentials and Home compared to the third quarter. Investors are particularly interested in Target's first investor day under new CEO Michael Fiddelke, seeking insights into the company's strategic direction and potential growth opportunities. BBY declined -0.61%, indicating mixed performance in the retail sector.
SOPHiA GENETICS (SOPH), a leader in AI-driven precision medicine, reported a 22% year-over-year increase in fourth-quarter revenue, reaching $21.7 million. Full-year revenue was $77.3 million, up 19% year-over-year. While revenue growth is strong, the company's IFRS net loss for the full year 2025 was $79.0 million, a 26% increase year-over-year. The adjusted EBITDA loss also increased by 3% year-over-year to $41.5 million. This highlights the ongoing challenge of balancing growth with profitability in the healthcare technology sector.
Civeo Corporation (CVEO) also reported its fourth quarter results, highlighting disciplined execution in a challenging macro environment. CVEO shares saw a slight increase of +0.47%. Belite Bio, Inc (BLTE) focused on developing therapies for inherited retinal diseases, saw shares decline -6.68%. Webtoon Entertainment (WBTN) shares increased +1.07%, after reporting revenue growth rate of approximately 8.66% as of September 30, 2025.
Expectations are set. Now comes execution.